V
VeraDermics
A medical dermatology company advancing first-in-class therapeutics that address real-world patient needs in under-innovated dermatology markets
About VeraDermics
VeraDermics is a pioneering company in the dermatology sector, specializing in the development of innovative and less painful treatments for skin conditions, particularly warts. The company leverages the clinical expertise of its team of board-certified dermatologists to identify significant unmet needs in dermatological care and develop targeted solutions. VeraDermics primarily serves patients suffering from common skin conditions, with a special focus on children who require less invasive and more comfortable treatment options. Operating within the pharmaceutical and healthcare markets, the company employs a research-driven business model, investing heavily in clinical trials and product development. Revenue is generated through the commercialization of their proprietary treatments, which are designed to be more effective and less painful than existing options. The company has successfully raised $20.7 million to advance its mission, underscoring its potential for growth and innovation in the dermatology field.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- San Antonio, United States
- Employees
- 44
- Open positions
- 6
- Dealroom signal
- 61.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Feb 2026 | $256M | $596M | Undisclosed | ↗ |
| SERIES COther financing | Oct 2025 | $150M | $600M | Viking Global Investors · Longitude Capital · SR One · Invus | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for VeraDermics is 35K monthly website visits, up 16.7% over the last three months. VeraDermics's team grew 37.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Connecticut Innovations
Prospect Hill Growth Partners- WAWerth Family Investment Associates
Suvretta Capital Management
Longitude Capital
Surveyor Capital
PhiFund Ventures
Osage University Partners- JAJW Childs Associates
Series B and later7 investors entered at this stage
SR One
Viking Global Investors
Invus
Infinitium
LifeSci Venture Partners
Marshall Wace
Columbia Threadneedle Investments
Other known investors1 additional known investor
University of Pennsylvania
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about VeraDermics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See VeraDermics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.